Europe
A vote to be held in 2026 could create Hogan Lovells Cadwalader, a $3.6bn giant with 3,100 lawyers across the Americas, EMEA and Asia Pacific
Varuni Paranavitane of Finnegan and IP counsel Lisa Ribes compare and contrast two recent AI copyright decisions from Germany and the UK
Exclusive in-house data uncovered by Managing IP reveals French firms underperform on providing value equivalent to billing costs and technology use
The new court has drastically changed the German legal market, and the Munich-based firm, with two recent partner hires, is among those responding
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access -
Sponsored by Gün and PartnersUğur Aktekin and Begüm Soydan Sayılkan of Gün + Partners highlight several decisions concerning the Turkish Patent and Trademark Office’s well-known trademark registry and say clarification of its standing is eagerly awaited
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald consider proposals under the European Commission’s Action Plan for Intellectual Property that aim to simplify extended protection for medicinal products through a unitary supplementary protection certificate
-
Sponsored by Bird & BirdKatharina Pehle of Bird & Bird considers the legislative progress and potential impact of a regulation on standard-essential patents as the proposal continues to draw criticism, despite approval by the European Parliament
-
Sponsored by InspicosAn EPO board of appeal decision has challenged the office’s standing in requiring applicants to adapt the description text of patent applications to be in accordance with amended claims, says Edward Farrington of Inspicos
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer and Gisela Grabow of Maiwald discuss potential changes to the EU pharmaceutical regulation and their potential impact on data and market protection timelines for medicinal products
European Jurisdictions